10-QPeriod: Q1 FY2015

BECTON DICKINSON & CO Quarterly Report for Q1 Ended Dec 31, 2014

Filed February 6, 2015For Securities:BDX

Summary

Becton Dickinson and Company (BDX) reported its fiscal first quarter 2015 results for the period ending December 31, 2014. The company announced a 1.8% increase in revenue to $2.051 billion, driven by volume growth partially offset by unfavorable foreign currency translation. Net income decreased to $236 million from $271 million in the prior year period, leading to diluted earnings per share of $1.20, down from $1.37. This decrease was influenced by significant acquisition-related costs, litigation charges, and financing expenses associated with the pending acquisition of CareFusion Corporation, which was announced during the quarter. The balance sheet shows a significant increase in cash and equivalents to $8.54 billion from $1.86 billion, largely due to proceeds from debt issuance to finance the CareFusion acquisition. Long-term debt also saw a substantial rise to $9.94 billion from $3.77 billion. Investors should note the strategic shift with the pending acquisition of CareFusion, which is expected to close by the second quarter of fiscal year 2015, creating a larger entity focused on medication management and patient safety. While the company's financial position remains strong, the increased debt and integration efforts related to the acquisition will be key areas to monitor.

Financial Highlights

50 data points
Beta

Revenue

$2.05B

51.0% Gross Margin

Net Income

$236.00M

11.5% Net Margin

EPS (Diluted)

$1.20

Total Assets

$18.50B

Cash & Equivalents

$8.54B

Free Cash Flow

$181.00M

Financial Statements
Beta
Revenue$2.05B
Cost of Revenue$1.01B
Gross Profit$1.04B
R&D Expenses$129.00M
SG&A Expenses$544.00M
Operating Expenses$1.70B
Operating Income$349.00M
Interest Expense$76.00M
Net Income$236.00M
EPS (Basic)$1.22
EPS (Diluted)$1.20
Shares Outstanding (Basic)192.84M
Shares Outstanding (Diluted)197.00M

Key Highlights

  • 1Revenue increased by 1.8% to $2.05 billion, driven by volume growth, offset by a 3.5% unfavorable foreign currency translation.
  • 2Net income decreased to $236 million ($1.20 EPS) from $271 million ($1.37 EPS) in the prior year, impacted by acquisition-related costs and litigation charges.
  • 3Significant increase in cash and equivalents to $8.54 billion from $1.86 billion, primarily due to $6.2 billion in senior unsecured notes issued to finance the pending CareFusion acquisition.
  • 4Long-term debt increased substantially to $9.94 billion from $3.77 billion, reflecting the financing for the CareFusion acquisition.
  • 5The company announced a definitive agreement to acquire CareFusion Corporation for approximately $12.2 billion, a major strategic move expected to close by Q2 FY2015.
  • 6Operating income for the Medical segment increased slightly to $304 million, while Life Sciences operating income decreased to $214 million.
  • 7Share repurchase program was suspended for FY2015 due to the pending CareFusion acquisition.

Frequently Asked Questions

The substantial increase in cash and equivalents from $1.86 billion to $8.54 billion is primarily due to the $6.2 billion in senior unsecured notes issued in December 2014 to finance the pending acquisition of CareFusion Corporation.

The acquisition of CareFusion, valued at approximately $12.2 billion, has led to significant financing costs, including $44 million in interest expense and $23 million in acquisition-related costs recorded in the current quarter. It has also led to a substantial increase in long-term debt and a suspension of share repurchases.

Net income decreased from $271 million to $236 million, and diluted EPS fell from $1.37 to $1.20. This decline was attributed to several factors, including acquisition-related costs ($23 million), financing costs ($44 million) associated with the CareFusion acquisition, and a $12 million charge for litigation-related attorney fees (RTI case).

The company's long-term debt increased significantly from $3.77 billion to $9.94 billion. This increase is largely due to the $6.2 billion of senior unsecured notes issued in December 2014 to fund the CareFusion acquisition and additional borrowings under a new term loan facility.